MS Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
MS Center Amsterdam, Department of Anatomy & Neurosciences, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Mult Scler. 2024 Feb;30(2):266-271. doi: 10.1177/13524585231225855. Epub 2024 Jan 18.
Extended interval dosing (EID) of natalizumab treatment is increasingly used in multiple sclerosis. Besides the clear anti-inflammatory effect, natalizumab is considered to have neuroprotective properties as well.
This study aimed to study the longitudinal effects of EID compared to standard interval dosing (SID) and natalizumab drug concentrations on brain atrophy.
Patients receiving EID or SID of natalizumab with a minimum radiological follow-up of 2 years were included. Changes in brain atrophy measures over time were derived from clinical routine 3D-Fluid Attenuated Inversion Recovery (FLAIR)-weighted magnetic resonance imaging (MRI) scans using SynthSeg.
We found no differences between EID ( = 32) and SID ( = 50) for whole brain (-0.21% vs -0.16%, = 0.42), ventricular (1.84% vs 1.13%, = 0.24), and thalamic (-0.32% vs -0.32%, = 0.97) annualized volume change over a median follow-up of 3.2 years. No associations between natalizumab drug concentration and brain atrophy rate were found.
We found no clear evidence that EID compared to SID or lower natalizumab drug concentrations have a negative impact on the development of brain atrophy over time.
纳武利尤单抗的延长间隔给药（EID）在多发性硬化症中的应用越来越多。除了明显的抗炎作用外，纳武利尤单抗还被认为具有神经保护作用。
本研究旨在研究 EID 与标准间隔给药（SID）和纳武利尤单抗药物浓度对脑萎缩的纵向影响。
纳入接受 EID 或 SID 纳武利尤单抗治疗且影像学随访至少 2 年的患者。使用 SynthSeg 从临床常规的三维液体衰减反转恢复（FLAIR）加权磁共振成像（MRI）扫描中得出脑萎缩指标随时间的变化。
我们发现 EID（n = 32）和 SID（n = 50）之间在全脑（-0.21% vs -0.16%， = 0.42）、脑室（1.84% vs 1.13%， = 0.24）和丘脑（-0.32% vs -0.32%， = 0.97）的年度体积变化上无差异，中位随访时间为 3.2 年。纳武利尤单抗药物浓度与脑萎缩率之间没有关联。
我们没有明确的证据表明 EID 与 SID 或较低的纳武利尤单抗药物浓度相比，对随时间发展的脑萎缩有负面影响。
Zotero 插件